Under‐representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database
British Journal of Clinical Pharmacology2019Vol. 85(4), pp. 838–844
Citations Over TimeTop 10% of 2019 papers
Abstract
The under-representation of elderly in clinical trials thereby challenging the external validity of benefit/risk assessments of launched drugs was confirmed. Priority should be given to a study population that is representative for the target population.
Related Papers
- → Use of the conditional marketing authorization pathway for oncology medicines in Europe(2015)56 cited
- → Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications(2018)29 cited
- → The Use of Food and Drug Administration Approved Medications for Unlabeled (Off-Label) Uses(1994)23 cited
- → European regulatory use and impact of subgroup evaluation in marketing authorisation applications(2017)2 cited
- → Marketing authorization procedures with negative opinion from EMA—tendencies and novelties in 2021–2022(2022)